Figure 3: Generating new NS5A mutation in mouse. | Scientific Reports

Figure 3: Generating new NS5A mutation in mouse.

From: Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment

Figure 3

(A) Serum HCV RNA levels in human hepatocyte chimeric mice inoculated with engineered full-genome HCV RNA from the wild type Ly strain via intrahepatic injection. Closed circle with a solid line, closed triangle with a dashed line and cross-mark with a dashed line represent the high chimeric rate mice (chimeric rate 78.9–93.2%), moderate chimeric rate mice (chimeric rate 57.6–70.3%) and relatively low chimeric rate mice (chimeric rate 46.4–56.1%), respectively. (B) Serum HCV RNA levels in a human hepatocyte chimeric mouse that was persistently infected with full-genome HCV RNA. The mouse was treated with 4 weeks of LDV monotherapy and deep sequencing was performed before and after treatment (at weeks 6 and 14). N.D., not detected, and S.D., signal detected but at lower quantification levels.

Back to article page